The Speak Foundation launched the LGMD Centers of Excellence, a network of clinics dedicated to improving care for people ...
The Speak Foundation today announced the launch of the LGMD Centers of Excellence, a national network of leading academic medical institutions designed to improve coordinated, multidisciplinary care ...
The advent of gene therapies, which can target specific variants, means pinpointing the genetic roots of each patient’s disease has taken on new importance, researchers said. A team of researchers ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
EVRY, France--(BUSINESS WIRE)--Atamyo Therapeutics, a biotechnology company specializing in the development of next-generation gene therapies for limb-girdle muscular dystrophy (LGMD), announced at ...
– U.S. FDA has confirmed that screening and dosing may proceed in Study SRP-9005-101 for LGMD2C/R5 – Enrollment and dosing completed in Study SRP-9004-102 for LGMD2D/R3 – Data expected for SRP-9003 ...
RESEARCH TRIANGLE PARK, N.C. , Aug. 3, 2023 /PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, ...
One of the first symptoms of LGMD is typically a weakening of the muscles in the hip and shoulder girdles. The hip girdle is a ring-like bone structure in the pelvic area, consisting of the pelvis, ...
Daughter Verena shares her personal story of living with Limb-girdle type 2A muscular dystrophy. The progressive disease affects muscles around the shoulders, limbs, hips, and thighs, making simple ...
(Reuters) -U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a muscular dystrophy patient who received a different, experimental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results